

Bulletin #756

June 29, 2009

BENEFIT CHANGES TO NBPDP

This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 29, 2009.

Included in this bulletin:

- **Regular Benefit Additions**
- **Special Authorization Additions**
- **Drugs Reviewed and Not Listed**
- **Reminder Notice - Only Claims from within NB reimbursed**

To subscribe or unsubscribe from the Bulletin e-mail notification list, please send a message to BC_nbpdp@medavie.bluecross.ca or call 1-800-332-3691. Bulletins are also available on the NBPDP web page: www.gnb.ca/0051/0212/index-e.asp

If you have any questions, please contact our office at 1-800-332-3691.

Yours truly,



Debbie LeBlanc
New Brunswick Prescription Drug Program

REGULAR BENEFIT ADDITIONS

Drug/Form/Route/Strength	Brand Name	DIN	Manufacturer	Plans	\$
Clindamycin Hydrochloride					
Cap Orl 300mg	Dalacin® C	2182866	PFI		
	Novo-Clindamycin	2241710	NOP		
	Apo-Clindamycin	2245233	APX	ABEFGVW	MAP
	Gen-Clindamycin	2258358	GPM		
	pms-Clindamycin	2294834	PMS		
Insulin glulisine 100IU/mL					
Liq Inj 10mL vial	Apidra®	2279460			
3mL pre-filled disposable	Apidra® Solostar®	2294346	SAV	EFG<18	AAC

Drugs no longer requiring special authorization

Efavirenz / tenofovir / emtricitabine					
Tab Orl 600/300/200mg	Atripla®	2300699	GIL	U	AAC
Tenofovir / emtricitabine					
Tab Orl 300/200mg	Truvada®	2274906	GIL	U	AAC

SPECIAL AUTHORIZATION ADDITIONS

Ambrisentan
(*Volibris™*)
5mg, 10mg tablets

For treatment of patients with pulmonary arterial hypertension (PAH), of at least World Health Organization (WHO) functional class III, which is associated with either idiopathic or connective tissue disease and who have failed to respond to or who have contraindications to, or who are not a candidate for sildenafil.

- Diagnosis of PAH should be confirmed by cardiac catheterization
- The maximum dose of ambrisentan that will be reimbursed is 10 mg daily
- Ambrisentan will not be approved when used concurrently with other endothelin receptor antagonists, epoprostenol, treprostinil or sildenafil.

Insulin glulisine
(*Apidra®*)
100IU/mL vials and
SoloSTAR pre-filled
pens

- For patients with type I or II diabetes who have experienced frequent episodes of postprandial hypoglycemia; have unpredictable mealtimes; have insulin resistance; or who are using continuous subcutaneous insulin infusion.

Prescriptions written by New Brunswick endocrinologists and internists do not require special authorization. Subsequent refills ordered by other practitioners will not require special authorization.

Note: Insulin glulisine is a regular benefit for Plans EFG<18 years of age.

SPECIAL AUTHORIZATION ADDITIONS

Rivaroxaban
(*Xarelto*[®])
10mg tablet

- For the prophylaxis of venous thromboembolism following total knee replacement or total hip replacement surgery, for up to 14 days as an alternative to low molecular weight heparins.
- The maximum dose of rivaroxaban that will be reimbursed is 10 mg daily for up to 14 days during a 6 month period.

Note: Subsequent requirements for prophylaxis within a 6 month period will require Special Authorization.

DRUGS REVIEWED AND NOT LISTED

The reviews of the following products found they did not offer a therapeutic and/or cost advantage over existing therapies. Requests for coverage through special authorization will not be considered.

Dabigatran etexilate	(<i>Pradax</i> [®])	75mg and 110mg capsules
Methylnaltrexone	(<i>Relistor</i> [™])	20mg/mL vial
Sitaxsentan - resubmission	(<i>Thelin</i> [™])	100mg tablet
Sodium Oxybate	(<i>Xyrem</i> [®])	500mg/mL oral solution

REMINDER – ONLY CLAIMS FROM WITHIN N.B. REIMBURSED

With the summer and vacation season fast approaching, this is a reminder that NBPDP cannot reimburse prescriptions filled out-of-province per the Regulations to the *Prescription Drug Payment Act*. Exceptions also specified in the Regulations include the following:

- Organ transplant (Plan R) - prescriptions for eligible drugs under Plan R may be filled by a pharmacy outside of New Brunswick, but within Canada, during the first 60 days after hospital discharge, but thereafter must be filled by a pharmacy or designated dispensing physician within New Brunswick.
- Human growth hormone (Plan T) - if the drug is received by the beneficiary on the prescription of a designated endocrinologist.